Huahai Pharmaceutical announced that Huaotai, a subsidiary of the company, and Huabo Biotech have received a drug clinical trial approval notice for new indications of HB0056 injection issued by the State Drug Administration and agreed to carry out clinical trials for chronic obstructive pulmonary disease indications.

Zhitongcaijing · 2d ago
Huahai Pharmaceutical announced that Huaotai, a subsidiary of the company, and Huabo Biotech have received a drug clinical trial approval notice for new indications of HB0056 injection issued by the State Drug Administration and agreed to carry out clinical trials for chronic obstructive pulmonary disease indications.